Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 4 clinical trials
Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study

The RECOVER study is a self-controlled case series to evaluate whether the addition of Fostemsavir (Rukobia) to a stable HIV regimen in virologically suppressed patients living with HIV who never experience optimal CD4 T-cell count recovery can result in meaningful increases in different immunologic parameters such as CD4 T-cell count, …

  • 11 Oct, 2022
  • 1 location
Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir (NewHorizon)

etravirine (ETR), at the time of initiation on DRV and/or ETR; Describe the clinical and laboratory profile of patients who ever received DRV and/or ETR every 6 months from the first data

Accepts healthy volunteers
  • 13 Apr, 2022
  • 4 locations
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women. (PANNA)

Due to the potential for pregnancy-induced changes in the pharmacokinetics of medication, one cannot assume that the currently licensed doses of the medication to be tested under this protocol lead to adequate exposure in an HIV-infected pregnant woman. For the agents under study no or limited pharmacokinetic data during pregnancy …

hiv antibody
antiretroviral agents
HIV Vaccine
antibody test
  • 07 Oct, 2022
  • 16 locations
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR)

The purpose of the Antiretroviral Pregnancy Registry (Registry) is to detect any major teratogenic effect involving any of the Registry drugs when administered to pregnant women. Registration is voluntary and confidential with information obtained from the health care provider. A Registry-assigned identifier allows for follow-up capability. Information on subjects is …

antiretroviral agents
HIV Vaccine
  • 04 May, 2022
  • 1 location